MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 597267 | Name: Ornithine glutamate dipeptide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ornithine glutamate dipeptide is an amino acid.

Chemical Structure

Ornithine glutamate dipeptide
Ornithine glutamate dipeptide
CAS#91388-18-0

Theoretical Analysis

MedKoo Cat#: 597267

Name: Ornithine glutamate dipeptide

CAS#: 91388-18-0

Chemical Formula: C10H19N3O5

Exact Mass: 261.1325

Molecular Weight: 261.27

Elemental Analysis: C, 45.97; H, 7.33; N, 16.08; O, 30.62

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Ornithine glutamate dipeptide; Orn-glu;
IUPAC/Chemical Name
((S)-2,5-diaminopentanoyl)-L-glutamic acid
InChi Key
RROQYZJPOZVQTM-BQBZGAKWSA-N
InChi Code
InChI=1S/C10H19N3O5/c11-5-1-2-6(12)9(16)13-7(10(17)18)3-4-8(14)15/h6-7H,1-5,11-12H2,(H,13,16)(H,14,15)(H,17,18)/t6-,7-/m0/s1
SMILES Code
O=C(O)CC[C@@H](C(O)=O)NC([C@H](CCCN)N)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 261.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Holmes RS. Comparative and evolutionary studies of ALDH18A1 genes and proteins. Chem Biol Interact. 2017 Oct 1;276:2-8. doi: 10.1016/j.cbi.2016.12.012. Epub 2016 Dec 16. PubMed PMID: 27989597. 2: Kishimoto S, Nishimura S, Hatano M, Igarashi M, Kakeya H. Total Synthesis and Antimicrobial Activity of Chlorocatechelin A. J Org Chem. 2015 Jun 19;80(12):6076-82. doi: 10.1021/acs.joc.5b00532. Epub 2015 Jun 5. PubMed PMID: 26018853. 3: Abd-El-Karem Y, Elbers T, Reichelt R, Steinbüchel A. Heterologous expression of Anabaena sp. PCC7120 cyanophycin metabolism genes cphA1 and cphB1 in Sinorhizobium (Ensifer) meliloti 1021. Appl Microbiol Biotechnol. 2011 Feb;89(4):1177-92. doi: 10.1007/s00253-010-2891-x. Epub 2010 Oct 12. PubMed PMID: 20938772. 4: Haynes TE, Li P, Li X, Shimotori K, Sato H, Flynn NE, Wang J, Knabe DA, Wu G. L-Glutamine or L-alanyl-L-glutamine prevents oxidant- or endotoxin-induced death of neonatal enterocytes. Amino Acids. 2009 May;37(1):131-42. doi: 10.1007/s00726-009-0243-x. Epub 2009 Feb 3. PubMed PMID: 19189199. 5: Atkinson M, Worthley LI. Nutrition in the critically ill patient: part II. Parenteral nutrition. Crit Care Resusc. 2003 Jun;5(2):121-36. PubMed PMID: 16573470. 6: Bentz EL, Goswami R, Moloney MG, Westaway SM. Stereoselective synthesis of conformationally constrained omega-amino acid analogues from pyroglutamic acid. Org Biomol Chem. 2005 Aug 7;3(15):2872-82. Epub 2005 Jul 1. PubMed PMID: 16032366. 7: Hass HG, Nägele T, Seeger U, Hösl F, Gregor M, Kaiser S. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)]. Z Gastroenterol. 2005 Apr;43(4):373-8. German. PubMed PMID: 15830303. 8: Chulin AN, Rodionov IL, Baidakova LK, Rodionova LN, Balashova TA, Ivanov VT. Preparation and reactivity of aminoacyl pyroglutamates. Facile synthesis of 10-membered-ring cyclic dipeptides derived from 1,4-diaminobutyric and glutamic acids. J Pept Sci. 2005 Mar;11(3):175-86. PubMed PMID: 15635648. 9: Butterworth RF. Brain edema in acute liver failure. Indian J Gastroenterol. 2003 Dec;22 Suppl 2:S59-61. Review. PubMed PMID: 15025258. 10: Delcker A, Turowski B, Mihm U, Raab P, Rusch O, Pilatus U, Zeuzem S, Zanella FE. Proton MR spectroscopy of neurometabolites in hepatic encephalopathy during L-ornithine-L-aspartate treatment--results of a pilot study. Metab Brain Dis. 2002 Jun;17(2):103-11. PubMed PMID: 12083335. 11: Mühling J, Fuchs M, Fleck C, Sablotzki A, Krüll M, Dehne MG, Gonter J, Weiss S, Engel J, Hempelmann G. Effects of arginine, L-alanyl-L-glutamine or taurine on neutrophil (PMN) free amino acid profiles and immune functions in vitro. Amino Acids. 2002;22(1):39-53. PubMed PMID: 12025873. 12: Marín JF, Mendiola P, Hernández MD, De Costa J, Zamora S. Influence of exercise on plasma and muscle free amino acids in trained rainbow trout. J Physiol Biochem. 1999 Dec;55(4):293-9. PubMed PMID: 10731080. 13: Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology. 1999 Sep;30(3):636-40. PubMed PMID: 10462368. 14: Rose C, Michalak A, Pannunzio P, Therrien G, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab Brain Dis. 1998 Jun;13(2):147-57. PubMed PMID: 9699922. 15: Gebhardt R, Beckers G, Gaunitz F, Haupt W, Jonitza D, Klein S, Scheja L. Treatment of cirrhotic rats with L-ornithine-L-aspartate enhances urea synthesis and lowers serum ammonia levels. J Pharmacol Exp Ther. 1997 Oct;283(1):1-6. PubMed PMID: 9336301. 16: Vogels BA, Karlsen OT, Mass MA, Boveé WM, Chamuleau RA. L-ornithine vs. L-ornithine-L-aspartate as a treatment for hyperammonemia-induced encephalopathy in rats. J Hepatol. 1997 Jan;26(1):174-82. PubMed PMID: 9148009. 17: Staedt U, Leweling H, Gladisch R, Kortsik C, Hagmüller E, Holm E. Effects of ornithine aspartate on plasma ammonia and plasma amino acids in patients with cirrhosis. A double-blind, randomized study using a four-fold crossover design. J Hepatol. 1993 Nov;19(3):424-30. PubMed PMID: 8151104. 18: Miyatake N, Kamo M, Satake K, Uchiyama Y, Tsugita A. Removal of N-terminal formyl groups and deblocking of pyrrolidone carboxylic acid of proteins with anhydrous hydrazine vapor. Eur J Biochem. 1993 Mar 15;212(3):785-9. PubMed PMID: 8462549. 19: Turinsky J, Long CL. Free amino acids in muscle: effect of muscle fiber population and denervation. Am J Physiol. 1990 Mar;258(3 Pt 1):E485-91. PubMed PMID: 2316643. 20: Ullrich KJ, Rumrich G, Wieland T, Dekant W. Contraluminal para-aminohippurate (PAH) transport in the proximal tubule of the rat kidney. VI. Specificity: amino acids, their N-methyl-, N-acetyl- and N-benzoylderivatives; glutathione- and cysteine conjugates, di- and oligopeptides. Pflugers Arch. 1989 Dec;415(3):342-50. PubMed PMID: 2622761.

View History

II399

II399